UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates

UBS maintains a 'Buy' on CVS Caremark (NYSE: CVS) price target raised $1 to $49.

UBS analyst says, "Following CVS’ 4Q11 conf call, we are raising our 2012 EPS estimate from $3.20 to $3.26 to now reflect some of the potential upside related to the WAG/ESRX dispute. Our PBM projections are essentially unchanged, while all the upside is captured in the retail segment. The key is to decipher timing of resolution between Walgreen (NYSE: WAG) / Express Scripps (Nasdaq: ESRX)." (UBS raises FY13 from $3.68 to $3.70)

For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.

Shares of CVS Caremark closed at $43.57 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners